Abstract
Overview
Introduction
Endometriosis is a painful, menstrual-related disorder that is thought to
affect approximately 10% of the female population of reproductive age. Despite
this large patient potential, growth of the endometriosis market has been
limited by low levels of investment, poor awareness among physicians and the
public, problematic diagnosis, and lack of effective therapies.
Scope
- Review of treatments and players in the seven major markets including
their strategies for success.
- Movement of patients, depending on their treatment goal, through the
referral and the treatment pathway.
- Overview of the pipeline including coverage of each of the novel
mechanisms of action currently being explored.
- Identification of the unmet need, supported by international opinion
leader insight.
Report Highlights
Supporting celebrity spokespeople is a useful strategy for pharmaceutical
companies to adopt in the endometriosis market in order to destigmatize the
disease and expand the patient population, as witnessed in the erectile
dysfunction and osteoporosis markets.
Imaging techniques, in particular ultrasonography, have the potential to
become the new gold-standard diagnostic procedure. Biomolecular and genetic
diagnostic tests, to replace CA-125, would be well received by physicians and
several are being trialed currently.
In the current litigious climate and given the return on investment based on
the potential patient population, opinion leaders advise that manufacturers of
new products would be justified in pursuing a specific endometriosis label.
Reasons to Purchase
- Quantify the number of reproductively aged women with endometriosis in the
general population and in gynecologic populations in the US, 5EU, and Japan
- Understand opinion leaders' views on topical issues and unmet need in the
endometriosis market.
- Assess the competitive environment upon launch of a product based on the
analysis of key pipeline products and R&D strategies.
View Cart
